ERSET, which is sponsored by the National Institute of Neurological Disorders and Stroke, a part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services, offers an opportunity for eligible participants and their families to learn about early treatment for mesial temporal lobe epilepsy (MTLE), the most common form of epilepsy. ERSET will also provide eligible participants with care at epilepsy centers in the United States, including Swedish Medical Center. One of 18 sites participating, Swedish is the only center west of Minnesota and north of San Francisco.
Research shows that MTLE may be progressive in nature, especially in children. As seizures continue, they can cause irreversible disturbances in nerve-cell function, preventing normal brain development. "Data suggests that seizures can cause memory loss and affect a child's ability to learn and pay attention in school," said David Vossler, M.D., Swedish Medical Center neurologist and the hospital's co-principal investigator on ERSET. "Persistence of seizures during adolescence and early adulthood commonly cause irreversible social and psychological consequences."
"This is an important study and we expect that it will answer key questions about treatment choices and the timing of surgical treatment when seizures are difficult to control," said Eric R. Hargis, president and CEO of the Epilepsy Foundation. "Deciding when or whether to continue treatment with medications or to have surgery can be difficult and stressful for people with epilepsy and their families. The results of this study will, we hope, make those decisions easier and in the long run will improve quality of life for hundreds of thousands of patients."
Thirty percent of individuals with epilepsy have seizures that are intractable, meaning their seizures do not respond to medications. MTLE is often found to be intractable, and seizure intractability may be predicted with a high degree of confidence after two antiepileptic medications have proven ineffective. There are more than 20 antiepileptic medications, and specific therapies often depend on a patient's seizure type and how long they have been having seizures.
Many clinicians remain uncertain about the cost, safety and success rates of surgery and consider it a last resort. The most current data available, which is from 1990, shows that only 2,000 of the 100,000 eligible patients actually underwent the procedure despite the failure of medications to control their seizures. Surgery for MTLE involves the removal of a small amount of brain tissue that is the source of a person's seizures. There have been medical reports, including one published in the Aug. 2, 2001, issue of The New England Journal of Medicine, that purport surgery is superior to the medical treatment of long-standing MTLE. Potential risks associated with surgery include memory impairment, infection and bleeding.
ERSET is looking to enroll approximately 200 participants across the United States. Eligible participants must be at least 12 years old and must also have experienced life-disrupting seizures for no more than two years. If they experienced seizures earlier in life that stopped and subsequently re-emerged, they may still be eligible for this clinical research study. In addition, participants must have tried at least two different antiepileptic medications.
ERSET participants will have a complete evaluation to determine if they are eligible for the research study. If determined eligible, participants are assigned to treatment by surgery with medication or by medication only, and all will receive antiepileptic medications based on the best possible plan designed by epilepsy experts. After two years of follow-up, eligible participants who received medication only will have the option to undergo surgery.
To learn more about ERSET, participation and who may be eligible, call 1-800-352-9424 or visit www.erset.net for information about the early treatment of MTLE and this clinical research study.
Swedish Medical Center is the largest, most comprehensive, not-for-profit health provider in the Pacific Northwest. Swedish is comprised of three hospital campuses (First Hill, Providence and Ballard), Swedish Home Care Services and Swedish Physicians - a network of 11 primary-care clinics. In addition to general medical and surgical care, Swedish is known as a regional referral center, providing specialized treatment in areas such as cardiac care, oncology, orthopedics, high-risk obstetrics, neurological care, sleep medicine, pediatrics, organ transplantation and clinical research. For more information, visit www.swedish.org.
Media note: We have identified a 39-year-old Woodinville, Wash. woman, who had suffered from MTLE since age 5 and just recently had surgery, who is willing to be interviewed. Since not a lot was known when she was a child about how surgery would affect her developing brain, surgery was delayed. As a result of that decision though, her adolescence and life as a young adult was made much more difficult because of sometimes having multiple seizures a week. For many years she couldn't drive and struggled through school. Then, in March of 1998, she opted to have anterior-tip lobectomy brain surgery. Since then, this new mom and licensed midwife has only had one seizure and now enjoys a dramatically improved, more active lifestyle. To arrange an interview with this woman and with an epilepsy expert at Swedish or for more information about ERSET, contact Ed Boyle at (206) 386-2748 or via firstname.lastname@example.org.
- To read the transcript of a story KOMO TV (ch. 4; ABC) in Seattle recently ran about ERSET, click here.
- To read the transcript of a story Ivanhoe Broadcast News distribution service recently ran about ERSET, click here.
- To read the transcript of a story KIRO TV (ch. 7; CBS) in Seattle recently ran about ERSET, click here.
- To read the transcript of a story KING TV (ch. 5; NBC) in Seattle recently ran about ERSET, click here.